Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial

INTRODUCTION: The role of prednisone in the prevention of androgen receptor antagonist-related rash and treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is unclear. This pilot trial (ChiCTR2200060388) aimed to investigate the feasibility of apalutamide combined with androgen depriv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Dingyuan, Chen, Wenqiang, Lai, Fei, Qiu, Mingxing, Li, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657800/
https://www.ncbi.nlm.nih.gov/pubmed/38023146
http://dx.doi.org/10.3389/fonc.2023.1110807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657800/
https://www.ncbi.nlm.nih.gov/pubmed/38023146
http://dx.doi.org/10.3389/fonc.2023.1110807

Ejemplares similares